Clinical Trials
11 trialsNCT04776655 2025-10-02
LIBImAb
Azienda USL Reggio Emilia - IRCCS
Phase 3 Recruiting
NCT06321081 2024-03-20
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
Beijing Hospital
Phase 2 Recruiting
NCT05839470 2023-11-15
Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05799443 2023-04-05
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT03380689 2021-03-08
SIRB2
Fujian Cancer Hospital
Phase 1 Withdrawn
NCT03222089 2018-03-27
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
Fujian Cancer Hospital
Phase 2 Withdrawn
NCT00557102 2012-12-11
ERBIFORT
National Cancer Institute, France
Phase 2 Completed
NCT00506168 2007-07-25
Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer
National Cancer Center, Korea
Phase 2 Terminated
NCT00506207 2007-07-25
TIROX
National Cancer Center, Korea
Phase 1 Unknown
NCT00506571 2007-07-25
TIROX2
National Cancer Center, Korea
Phase 2 Unknown
NCT00507143 2007-07-25
Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan
National Cancer Center, Korea
Phase NA Unknown